화상 연고 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the burn ointment market size is expected to grow from USD 1.13 billion in 2025 to USD 1.2 billion in 2026 and is forecast to reach USD 1.59 billion by 2031 at 5.86% CAGR over 2026-2031.

This report is Segmented by Product Type (Topical Antibiotics, Silver-Based Ointments, Iodine-Based Ointments and More), Depth of Burn (First-Degree (Minor) Burns, and More), End User (Hospitals & Burn Centers and More), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Burn Ointment Market Trends and Insights

Rising Incidence of Burn Injuries in LMICs

Fire-related mortality remains high in low- and middle-income countries where only a third of hospitals run dedicated burn wards. Urbanization raises household fuel hazards, and factory expansion heightens industrial accidents that demand rapid topical intervention. India's health-care outlay rose 12.59% in 2025, enabling state hospitals to stock multipurpose antimicrobial gels for rural outreach programs. Governments now bundle burn ointment procurement with trauma-care kits distributed to community clinics. This structural demand lifts baseline volumes for manufacturers that supply value-priced packs while licensing core technology from multinational partners. As emergency departments report shorter patient stays, low-cost formulations become a stop-gap between first aid and referral care, which fuels the burn ointment market.

Growing Patient Awareness & Access to Advanced Treatment

Telehealth portals teach patients to distinguish between superficial and partial-thickness burns and to begin self-application of medicated creams within hours of injury. Payers in the United States reimburse skin-substitute grafts only after 4 weeks of failed conservative therapy, a policy that indirectly stimulates early topical care using higher-end formulations. Social-media campaigns led by burn-survivor foundations spotlight faster healing times linked to silver and sustained-release nanogels, shaping consumer perception of product efficacy. Europe's outpatient clinics now schedule digital follow-ups rather than inpatient stays, cutting overhead costs and cementing the role of the burn ointment industry in value-based care models.

Antibiotic Resistance & Local Side-Effects

A global study across 65 hospitals found that 32.4% of burn patients received systemic antibiotics within a week of injury, fueling resistance in Pseudomonas and Acinetobacter strains. Clinicians are cautious about prolonged topical antibiotic use because of contact dermatitis risks that delay re-epithelialization. In Rwanda, a pediatric case of pan-drug-resistant Pseudomonas raised alarm over cross-border pathogen spread. Hospitals respond by rotating antiseptic classes and integrating cold-plasma therapy, reducing dependence on conventional ointments. These limitations dampen usage volumes and place a ceiling on the burn ointment market until alternative formulations overcome resistance hurdles.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Adoption of Silver-Based Antimicrobial Ointments
2. Military Field-Use Procurement for Combat Burns
3. High Cost of Advanced Silver/Biologic Therapies

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Topical antibiotics dominated revenue with a 37.95% burn ointment market share in 2025, underpinned by clinical familiarity and low unit cost. Silver creams, however, are set to chart an 8.13% CAGR to 2031 as hospitals shift protocols toward broad-spectrum coverage that counters biofilm formation. Iodine products retain relevance for deep or contaminated burns because of their oxidative kill mechanism but record slower growth on account of staining and cytotoxicity concerns. Carbon-dot carrier systems developed in 2025 extend active release over three days, which reduces nursing time and improves patient comfort.

Competitive differentiation hinges on patentable delivery matrices rather than the active ingredient itself. Firms embed silver ions within hydrocolloid layers that swell on contact with exudate, controlling moisture while releasing metal over 48-72 hours. Combo formulations that marry silver with lidocaine cater to emergency responders needing infection management and analgesia in one step. Regulatory upgrades mean Class III silver gels must now include data on microbial resistance trajectories, prompting richer post-market surveillance programs. As advanced products gain approvals, premium pricing contributes outsize dollar growth even if volume gains trail traditional creams. The interplay of efficacy, compliance, and cost will shape the long-term competitive fabric of the burn ointment market.

Superficial first-degree burns remained common, capturing 46.05% of 2025 sales value because of their high frequency in domestic settings. Yet third-degree burns are projected to register a 7.41% CAGR as complex trauma from industrial blasts, chemical spills, and military actions requires high-value topical care. These full-thickness injuries demand moisture control, antimicrobial coverage, and regenerative support, making them suitable candidates for bioactive gels laced with growth factor mimetics.

Treatment pathways now emphasize debridement within three days followed by sustained-release ointment application to curtail infection and speed graft readiness. Formulators researching exosome-like vesicles seek to trigger collagen deposition without fibroblast overstimulation that leads to hypertrophic scarring. Hospitals deploy advanced imaging to map wound depth and guide dosage amounts, improving cost efficiency for premium products. The burn ointment market size for third-degree applications thus outpaces unit shipments because of double-digit price points. As defense agencies refine battlefield protocols, third-degree burn solutions built for military use may trickle into civilian trauma centers, broadening the revenue base.

Complete Report Scope:

• By Product Type
  • Topical Antibiotics
  • Silver-based Ointments
  • Iodine-based Ointments
  • Combination / Others
• By Depth of Burn
  • First-degree (Minor) Burns
  • Second-degree (Partial Thickness) Burns
  • Third-degree (Full Thickness) Burns
• By End User
  • Hospitals & Burn Centers
  • Ambulatory Surgical Centers
  • Home Healthcare Settings
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America, with its 37.55% share, remains the largest regional contributor, leveraging advanced trauma systems, broad insurance coverage, and sustained military R&D funding that validates premium burn ointment protocols. United States procurement channels continue to funnel cutting-edge silver-based products into civilian hospitals after demonstrating efficacy on the battlefield. Canada's single-payer model negotiates national tenders that favor cost-effective generics yet still allocates budget for pediatric burn units deploying bioactive gels. Mexico's private hospitals import U.S. formulations as medical tourism grows, thereby widening the regional distribution footprint.

Asia-Pacific is the fastest-growing cluster, registering an 8.68% CAGR through 2031 as healthcare modernization programs unlock capital budgets for burn centers. India's state insurance schemes introduced in 2024 reimburse topical silver for high-risk patients, boosting baseline demand. China's provincial governments co-fund wound-care innovation hubs that incubate local nanogel start-ups, which tap domestic e-commerce platforms for rapid scale. Southeast Asian economies, grappling with industrial corridor fires and domestic cooking accidents, import mid-tier antimicrobial creams that balance cost and performance. Japan introduces performance-based reimbursement that rewards faster epithelialization, pushing hospitals toward sustained-release platforms. France adds silver-based gels to mandatory emergency-room stocks following guidance from its national public health agency. Eastern European markets lean on EU structural funds to renovate trauma facilities, creating incremental demand for staple antibiotic creams.

The Middle East and Africa remain underpenetrated yet promising. Gulf nations procure advanced biologic gels for expatriate-dense construction zones where burns from gas explosions are prevalent. North African countries collaborate with non-governmental organizations to distribute basic antimicrobial ointments at public clinics, improving first-aid response times. Sub-Saharan markets adopt mobile-health apps that direct patients to community burn units stocked with single-use sachets, enhancing treatment reach despite infrastructure constraints. South America sees moderate uptake, with Brazil investing in regional skin banks that will underpin longer-term demand for infection-control ointments. Collectively, these geographic nuances ensure that the burn ointment market continues its steady global climb.

1. Solventum Corporation
2. Smiths Group
3. Johnson & Johnson
4. Convatec
5. Cardinal Health
6. GlaxoSmithKline
7. Pfizer
8. Cipla
9. Sun Pharmaceuticals Industries
10. Perrigo Company
11. Mankind Pharma
12. DeRoyal Industries
13. Molnlycke Health Care
14. Leo Pharma
15. Medline Industries
16. B. Braun
17. Acelity (KCI)
18. Integra LifeSciences
19. Morepen
20. Trio Lifescience Pvt. Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence Of Burn Injuries In LMICs
  • 4.2.2 Growing Patient Awareness & Access To Advanced Treatment
  • 4.2.3 Rapid Adoption Of Silver-Based Antimicrobial Ointments
  • 4.2.4 Military Field-Use Procurement For Combat Burns
  • 4.2.5 Lithium-Battery & Vaping Explosions Increasing Outpatient Burns
  • 4.2.6 Nanotechnology-Enabled Sustained-Release Formulations
• 4.3 Market Restraints
  • 4.3.1 Antibiotic Resistance & Local Side-Effects
  • 4.3.2 High Cost Of Advanced Silver/Biologic Therapies
  • 4.3.3 Regulatory Re-Classification Of Topical Antimicrobials
  • 4.3.4 Silver Supply-Chain Price Volatility
• 4.4 Porter's Five Forces
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitutes
  • 4.4.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Topical Antibiotics
  • 5.1.2 Silver-based Ointments
  • 5.1.3 Iodine-based Ointments
  • 5.1.4 Combination / Others
• 5.2 By Depth of Burn
  • 5.2.1 First-degree (Minor) Burns
  • 5.2.2 Second-degree (Partial Thickness) Burns
  • 5.2.3 Third-degree (Full Thickness) Burns
• 5.3 By End User
  • 5.3.1 Hospitals & Burn Centers
  • 5.3.2 Ambulatory Surgical Centers
  • 5.3.3 Home Healthcare Settings
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies & Drug Stores
  • 5.4.3 Online Pharmacies
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Solventum Corporation
  • 6.3.2 Smith & Nephew PLC
  • 6.3.3 Johnson & Johnson
  • 6.3.4 ConvaTec Group PLC
  • 6.3.5 Cardinal Health Inc.
  • 6.3.6 GlaxoSmithKline PLC
  • 6.3.7 Pfizer Inc.
  • 6.3.8 Cipla Ltd.
  • 6.3.9 Sun Pharmaceutical Industries Ltd.
  • 6.3.10 Perrigo Company PLC
  • 6.3.11 Mankind Pharma
  • 6.3.12 DeRoyal Industries Inc.
  • 6.3.13 Molnlycke Health Care AB
  • 6.3.14 LEO Pharma A/S
  • 6.3.15 Medline Industries LP
  • 6.3.16 B. Braun Melsungen AG
  • 6.3.17 Acelity (KCI)
  • 6.3.18 Integra LifeSciences
  • 6.3.19 Dr. Morepen
  • 6.3.20 Trio Lifescience Pvt. Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment